Abivax SA

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. Show More...

  • Website https://www.abivax.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 5.28 EUR
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share EUR -0.64 -0.55 -1.64 -1.47 -1.13 -1.55 -2.51 -2.51
    Dividends EUR
    Payout Ratio % *
    Shares Mil 9.0 9.0 10.0 10.0 10.0 10.0 12.0 12.0
    Book Value Per Share * EUR 8.34 6.51 5.18 4.03 1.72 1.52
    Free Cash Flow Per Share * EUR -0.23 -2.48 -1.26 -1.2 -1.75
    Return on Assets % -15.32 -21.19 -27.93 -20.91 -19.62 -29.34 -57.92 -57.92
    Financial Leverage (Average) 1.13 1.12 1.06 1.07 1.11 1.56 2.78 2.78
    Return on Equity % -17.32 -23.84 -30.19 -22.27 -21.4 -38.2 -115.06 -115.06
    Return on Invested Capital % -15.87 -22.16 -29.31 -22.47 -21.4 -33.0 -68.73 -68.73
    Interest Coverage -43.74 -79.87 -108.36 -427.05 -452.97 -40.72 -19.77 -19.77
    Current Ratio 2.64 2.98 10.67 7.32 3.79 1.08 0.55 0.55
    Quick Ratio 2.62 2.81 9.75 6.05 3.09 0.81 0.35 0.35
    Debt/Equity 0.07 0.06